MX2022001975A - Composiciones, formulaciones y produccion y purificacion de interleucinas. - Google Patents

Composiciones, formulaciones y produccion y purificacion de interleucinas.

Info

Publication number
MX2022001975A
MX2022001975A MX2022001975A MX2022001975A MX2022001975A MX 2022001975 A MX2022001975 A MX 2022001975A MX 2022001975 A MX2022001975 A MX 2022001975A MX 2022001975 A MX2022001975 A MX 2022001975A MX 2022001975 A MX2022001975 A MX 2022001975A
Authority
MX
Mexico
Prior art keywords
individual
purification
methods
cholix
formulations
Prior art date
Application number
MX2022001975A
Other languages
English (en)
Inventor
Derek Maclean
Randall J Mrsny
Tahir Mahmood
James Andrew Whitney
Sean Dalziel
John Koleng
Amir Porat
Charles Olson
Weijun Feng
Kevin Yin
Bittoo Kanwar
Sally Postlethwaite
Hyojin Kim
Khushdeep Mangat
Rajendra Tandale
Marvin Garovoy
Elizabeth Bhatt
Original Assignee
Applied Molecular Transport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/050708 external-priority patent/WO2020096695A1/en
Application filed by Applied Molecular Transport Inc filed Critical Applied Molecular Transport Inc
Publication of MX2022001975A publication Critical patent/MX2022001975A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Water Supply & Treatment (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente se describen proteínas de fusión de cholix-IL-10 y métodos de uso de las mismas, que se pueden caracterizar por una respuesta distinta en un individuo cuando se administra. Esta respuesta distinta puede comprender cambios en los niveles de uno o más marcadores en el individuo y/o co-localización de IL-10 en la lamina propia del individuo. En la presente, en algunas modalidades, se describen adicionalmente formulaciones orales de las proteínas de fusión cholix-IL-10. En la presente se describen métodos para la purificación de un constructo de administración de IL-10, que incluyen métodos para replegamiento y enriquecimiento, que pueden dar por resultado el mantenimiento de un alto porcentaje de los constructos de administración de IL-10 en la forma dimérica biológicamente activa. En la presente se describen formulaciones orales configuradas para liberación específica en sitio de una proteína terapéutica en el intestino delgado o colon. En algunos casos, la proteína terapéutica está en la forma diméroca, tal como un constructo de administración de IL-10 capaz de cruzar el epitelio intestinal.
MX2022001975A 2019-08-16 2020-08-14 Composiciones, formulaciones y produccion y purificacion de interleucinas. MX2022001975A (es)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201962888144P 2019-08-16 2019-08-16
US201962888237P 2019-08-16 2019-08-16
US201962887963P 2019-08-16 2019-08-16
US201962887933P 2019-08-16 2019-08-16
US201962898899P 2019-09-11 2019-09-11
US201962898729P 2019-09-11 2019-09-11
US201962898709P 2019-09-11 2019-09-11
US201962898934P 2019-09-11 2019-09-11
PCT/US2019/050708 WO2020096695A1 (en) 2018-11-07 2019-09-11 Cholix-derived carriers for oral delivery of heterologous payload
US201962939495P 2019-11-22 2019-11-22
US202062970627P 2020-02-05 2020-02-05
US202062971126P 2020-02-06 2020-02-06
US202062986579P 2020-03-06 2020-03-06
US202062986557P 2020-03-06 2020-03-06
US202063013309P 2020-04-21 2020-04-21
US202063020996P 2020-05-06 2020-05-06
US202063033077P 2020-06-01 2020-06-01
US202063055886P 2020-07-23 2020-07-23
PCT/US2020/046545 WO2021034727A1 (en) 2019-08-16 2020-08-14 Compositions, formulations, and interleukin production and purification

Publications (1)

Publication Number Publication Date
MX2022001975A true MX2022001975A (es) 2022-03-11

Family

ID=74660606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001975A MX2022001975A (es) 2019-08-16 2020-08-14 Composiciones, formulaciones y produccion y purificacion de interleucinas.

Country Status (14)

Country Link
US (4) US11160869B2 (es)
EP (1) EP3844169A4 (es)
JP (1) JP2022544624A (es)
KR (1) KR20220066056A (es)
CN (1) CN114599665A (es)
AU (1) AU2020331939A1 (es)
BR (1) BR112022002962A2 (es)
CA (1) CA3150859A1 (es)
CL (1) CL2022000376A1 (es)
CO (1) CO2022003000A2 (es)
IL (1) IL290535A (es)
MX (1) MX2022001975A (es)
TW (1) TW202120521A (es)
WO (1) WO2021034727A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP3762009B1 (en) 2018-03-08 2022-05-11 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
CN113347997A (zh) 2018-11-07 2021-09-03 应用分子运输公司 用于经口递送异源有效载荷的Cholix衍生的携带体
EP3844169A4 (en) 2019-08-16 2021-12-15 Applied Molecular Transport Inc. COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKINS
CN113789333B (zh) * 2021-09-07 2023-07-14 中国人民解放军军事科学院军事医学研究院 Chi3l1在调控hUC-MSCs抑制Th17分化介导的免疫调节作用上的应用
WO2023196532A1 (en) * 2022-04-08 2023-10-12 Applied Molecular Transport Inc. Chimeric il-10/carrier constructs for treatment of pouchitis and methods of use

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2643653A (en) 1951-07-19 1953-06-30 Heidrich John Pill injector
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5272065A (en) 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US6051405A (en) 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US5807832A (en) 1987-06-09 1998-09-15 Biotech Australia Pty Limited Oral delivery of biologically active substances bound to vitamin B12
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
DE69131449T2 (de) 1990-05-11 1999-11-25 Us Health Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität
MX9200161A (es) 1991-01-16 1992-07-01 Schering Corp Uso de interleucina-10 en inmunoterapia adoptiva de cancer
GB9112553D0 (en) 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
AU675440B2 (en) 1992-06-18 1997-02-06 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant (pseudomonas) exotoxin with increased activity
US20020034727A1 (en) 1992-11-02 2002-03-21 Genentech, Inc. Compaction assay for assessment of respiratory disease therapy
EP0682524B1 (en) 1993-02-02 2001-10-04 XOMA Technology Ltd. Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
GB9420355D0 (en) 1994-10-10 1994-11-23 Univ Nottingham Preparation of protein microspheres, films and coatings
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US5811409A (en) 1995-06-05 1998-09-22 Synsorb Biotech, Inc. Treatment of cholera
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
WO1999006429A1 (fr) 1997-08-01 1999-02-11 Toray Industries, Inc. Stabilisation de proteines utiles et compositions a base de proteines utiles
US6342611B1 (en) 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
US6251392B1 (en) 1997-10-20 2001-06-26 Epicyte Pharmaceuticals, Inc. Epithelial cell targeting agent
US6592847B1 (en) 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7053200B1 (en) 1999-06-01 2006-05-30 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
EP1220682B1 (en) 1999-10-04 2006-11-22 Novartis Vaccines and Diagnostics, Inc. Stabilized liquid polypeptide-containing pharmaceutical compositions
US6838553B1 (en) 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
EP1242122B1 (en) 1999-10-22 2009-09-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Delivery of proteins across polar epithelial cell layers
US20030186386A1 (en) 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
JP4873818B2 (ja) 2000-05-16 2012-02-08 ボルダー バイオテクノロジー， インコーポレイテッド 遊離システイン残基を含有するタンパク質をリフォールディングする方法
DK1379273T3 (da) 2000-11-27 2009-11-09 Powderject Vaccines Inc Nukleinsyreadjuvanser
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
WO2002057296A1 (en) * 2001-01-16 2002-07-25 Københavns Universitet A method for refolding of proteins
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
JP4339598B2 (ja) 2001-05-23 2009-10-07 デュオトール アーベー 毒素サブユニットまたはそのフラグメントと共に、又はこれとコンジュゲートされたアレルゲンの経皮投与によるアレルギー反応の抑制
US20040219240A1 (en) * 2001-06-20 2004-11-04 Babish John G. Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
PT1476138E (pt) * 2002-02-21 2012-02-14 Valeant Internat Barbados Srl Formulações de libertação modificada de pelo menos uma forma de tramadol
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
EP1382614A1 (en) 2002-07-15 2004-01-21 Bayer HealthCare AG Process for the purification of interleukin-4 and its muteins
JP4623625B2 (ja) 2003-07-24 2011-02-02 株式会社ＡＭＢｉＳ ヘテロ型５量体組換えワクチン
EP1522585A1 (en) 2003-10-09 2005-04-13 Plant Research International B.V. Chimeric carrier molecules for the production of mucosal vaccines
US20080317761A1 (en) 2004-04-28 2008-12-25 The Trustees Of The University Of Pennsylvania Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
US20050281885A1 (en) 2004-06-21 2005-12-22 Egilmez Nejat K Method for treating inflammatory bowel disease by oral administration of IL-10
US20090155297A1 (en) 2004-10-04 2009-06-18 Trinity Biosystems, Inc. Methods and Compositions for Inducing an Immune Response Against Multiple Antigens
WO2006044205A2 (en) 2004-10-04 2006-04-27 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
US7611714B2 (en) 2004-10-04 2009-11-03 Trinity Biosystems, Inc. Methods and compositions for immunizing against Pseudomonas infection
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
AU2006247188A1 (en) 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
EP2311854B1 (en) 2005-07-29 2013-04-17 The Government of the United States of America, as represented by the Secretary of Health and Human Services Mutated pseudomonas exotoxins with reduced antigenicity
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
CA2631981A1 (en) 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
WO2007067596A2 (en) 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
EP1987058B1 (en) 2006-02-10 2010-05-12 ZymoGenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
US20090305978A1 (en) 2006-03-16 2009-12-10 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
JP2010500967A (ja) 2006-07-20 2010-01-14 ザ ジェネラル ホスピタル コーポレイション コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット
US20090092660A1 (en) 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
EP2057189B1 (en) 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
US20100196277A1 (en) 2006-10-09 2010-08-05 The University Of North Carolina At Chapel Hill Nanoparticle compositions for controlled delivery of nucleic acids
JP2010509363A (ja) 2006-11-08 2010-03-25 ノババックス，インコーポレイテッド 固体剤形の多相医薬組成物の製造方法
CN101674813A (zh) 2007-01-22 2010-03-17 诺瓦瓦克斯股份有限公司 水溶性差的药物的用于减小进食/禁食差异性和改善口服生物利用度的多相药物制剂
CA2683407C (en) 2007-04-04 2016-09-20 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
WO2008147526A1 (en) 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
WO2009014650A2 (en) 2007-07-20 2009-01-29 The General Hospital Corporation Recombinant vibrio cholerae exotoxins
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
US20110177155A1 (en) 2007-08-21 2011-07-21 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells
AU2009226972B2 (en) 2008-03-17 2014-05-29 Gerhard Heusipp YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
US20110250199A1 (en) 2008-06-04 2011-10-13 The Government of the United States of America as represented by the Secretary of the Department.... Immunotoxins and uses thereof
KR20190064664A (ko) 2008-10-02 2019-06-10 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
WO2011009624A1 (en) 2009-07-22 2011-01-27 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
AU2010277560B2 (en) 2009-07-31 2014-12-11 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CN105541978B (zh) 2010-09-15 2019-12-13 兰德尔·J·米斯尼 使用细菌毒素衍生的转运序列递送生物活性剂的系统和方法
US8697132B2 (en) * 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
EP2667898A1 (en) 2011-01-26 2013-12-04 Cenix Bioscience GmbH Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
WO2012110596A1 (en) 2011-02-16 2012-08-23 Friedrich-Alexander-Universität Erlangen-Nürnberg Fusion protein for the treatment of immunologic or allergic reactions
EP3653224A1 (en) 2011-06-29 2020-05-20 Rani Therapeutics, LLC Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8877161B2 (en) 2011-10-19 2014-11-04 Georgia Regents Research Institute, Inc. GM1-like peptides and uses thereof
WO2013130913A1 (en) 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
CA2875743A1 (en) 2012-06-14 2013-12-19 Sanofi Exendin-4 peptide analogues
JP2016503771A (ja) 2012-12-21 2016-02-08 サノフイ エキセンジン−４誘導体
WO2014094176A1 (en) 2012-12-21 2014-06-26 Oncozyme Pharma Inc. Uses and methods for the treatment of liver diseases or conditions
CA2903587C (en) 2013-03-15 2021-09-28 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
AU2014257123A1 (en) 2013-04-24 2015-10-15 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015070077A1 (en) 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Methods of use for il-22 in the treatment of gastrointestinal graft vs. host disease
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
IL287490B (en) 2014-01-27 2022-08-01 Molecular Templates Inc Shiga toxin nonvaccine effector subunit-containing polypeptides for mammalian applications
US10624955B2 (en) 2014-05-07 2020-04-21 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CN106573065A (zh) * 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
JP6910949B2 (ja) 2014-08-14 2021-07-28 ブラウン ユニバーシティ タンパク質を安定化させ、送達するための組成物
KR20170084033A (ko) 2014-10-22 2017-07-19 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
CA2969574A1 (en) * 2014-12-23 2016-06-30 Armo Biosciences, Inc. Methods of improving yield in recombinant protein production
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
AU2016298210B2 (en) 2015-07-28 2021-12-09 Board Of Regents, The University Of Texas System Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
WO2017062920A1 (en) 2015-10-07 2017-04-13 Chopra Sunandini Nanoparticles with ph triggered drug release
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CN108697907A (zh) 2016-01-06 2018-10-23 耶达研究及发展有限公司 用于治疗恶性疾病、自身免疫疾病和炎性疾病的组合物和方法
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
WO2017210684A1 (en) 2016-06-03 2017-12-07 New York University Methods and reagents for modulating macrophage phenotype
CA3026393C (en) 2016-06-22 2023-03-14 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
US20190257832A1 (en) 2016-07-18 2019-08-22 Philippe Ulsemer Natural microorganisms which are naturally capable of binding toxins and/or toxin receptors
CA3035414C (en) 2016-08-29 2022-02-22 The Regents Of The University Of California Topical formulations based on ionic species for skin treatment
EP3523274A4 (en) 2016-10-06 2020-05-13 Orbus Therapeutics, Inc. FORMULATIONS FOR THE ADMINISTRATION OF EFLORNITHIN
AU2017373962B2 (en) 2016-12-07 2022-03-31 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
EP3554346B1 (en) 2016-12-14 2024-01-31 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2019036243A1 (en) 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
EP3600440A1 (en) 2017-03-20 2020-02-05 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
US20200048321A1 (en) 2017-03-24 2020-02-13 Orpheus Bioscience Inc. Pantids for treatment of autoimmune disorders
CA3054156A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
US20200323772A1 (en) 2017-08-15 2020-10-15 Progenity, Inc. Treatment of inflammatory disease using ingestible device to release immune modulator
US11674950B2 (en) 2017-10-31 2023-06-13 Dana-Farber Cancer Institute, Inc. Methods determining and treating cellular resistance to ADP-rtbosylating toxin
PT3762009T (pt) * 2018-03-08 2022-08-22 Applied Molecular Transport Inc Construções de administração derivadas de toxinas para administração oral
EP3762009B1 (en) 2018-03-08 2022-05-11 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
US20210009678A1 (en) 2018-03-23 2021-01-14 North Carolina State University Methods and compositions for allergic disorders
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2020023389A1 (en) 2018-07-23 2020-01-30 Sienna Biopharmaceuticals, Inc. Reduced exposure compositions modulating therapeutic targets
EP3610862A1 (en) 2018-08-14 2020-02-19 Apillet APS Novel oral composition
JP2022506990A (ja) 2018-11-07 2022-01-17 アプライド モレキュラー トランスポート インコーポレイテッド トランスサイトーシスのための送達構築物および関連する方法
CN113347997A (zh) 2018-11-07 2021-09-03 应用分子运输公司 用于经口递送异源有效载荷的Cholix衍生的携带体
US20200140511A1 (en) 2018-11-07 2020-05-07 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
BR112021013337A2 (pt) 2019-01-07 2021-11-09 Bactolife Aps Proteínas de ligação a patógenos
MX2021013736A (es) 2019-05-10 2021-12-10 Glaxosmithkline Biologicals Sa Produccion de conjugados.
BR112022002975A2 (pt) 2019-08-16 2022-06-28 Applied Molecular Transport Inc Composições e partículas para aplicação de carga útil
EP3844169A4 (en) 2019-08-16 2021-12-15 Applied Molecular Transport Inc. COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKINS
WO2021155281A1 (en) 2020-01-31 2021-08-05 Applied Molecular Transport Inc. Compositions and methods for treatment of celiac disease

Also Published As

Publication number Publication date
US11214606B2 (en) 2022-01-04
WO2021034727A1 (en) 2021-02-25
US20220112259A1 (en) 2022-04-14
TW202120521A (zh) 2021-06-01
CN114599665A (zh) 2022-06-07
EP3844169A1 (en) 2021-07-07
CL2022000376A1 (es) 2022-11-25
KR20220066056A (ko) 2022-05-23
AU2020331939A1 (en) 2022-03-24
US20210171597A1 (en) 2021-06-10
EP3844169A4 (en) 2021-12-15
BR112022002962A2 (pt) 2022-07-05
CO2022003000A2 (es) 2022-07-08
CA3150859A1 (en) 2021-02-25
US11479593B2 (en) 2022-10-25
US20220089666A1 (en) 2022-03-24
JP2022544624A (ja) 2022-10-19
US11466067B2 (en) 2022-10-11
IL290535A (en) 2022-04-01
US11160869B2 (en) 2021-11-02
US20210154304A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
MX2022001975A (es) Composiciones, formulaciones y produccion y purificacion de interleucinas.
JP7275049B2 (ja) Ｉｌ－２改変体
CN103501805B (zh) 调节γ-C-细胞因子活性的组合物及方法
ES2328751T3 (es) Liberacion de polipeptidos biologicamente activos.
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
DE60330767D1 (de) Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen
JP6949184B2 (ja) 治療的な使用のための、核酸送達のための治療用ファージおよび方法
WO2017190684A1 (zh) 白细胞介素组合及其用途
TR200801336T1 (tr) Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
TW200637615A (en) Therapeutic peptide formulations with improved stability
AR078383A1 (es) Formulaciones en comprimido de la (4'-trifluorometilfenil ) amida del acido (z) -2- ciano-3- hidroxibut-2-enoico con mayor estabilidad
CN108350032A (zh) 调节γC-细胞因子活性
EA202191280A1 (ru) Конструкции для доставки для трансцитоза и связанные способы
CO2022000062A2 (es) Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
CL2022002429A1 (es) Anticuerpos anti-interleucina-33 y usos de estos.
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
NI202000071A (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos
CN109562154A (zh) 带有修饰hsp70域的抗原结合融合蛋白
ES2659586T3 (es) Proteínas de fusión quiméricas y partículas similares a virus de VP2 de Birnavirus
CL2022000118A1 (es) Formulaciones orales de edaravone y método de fabricación de las mismas.
CN110506050A (zh) γC细胞因子活性的稳定调节剂
AR124866A2 (es) Composiciones, formulaciones y producción y purificación de interleucina
MX2021005910A (es) Formulacion de proteina de alta concentracion.